ライフサイエンスコーパス: 1,25-dihydroxyvitamin D3

1 glutaminase promoter activity in response to 1,25-dihydroxyvitamin D3.

2 M, or IL-1 but not by parathyroid hormone or 1,25-dihydroxyvitamin D3.

3 hormones especially parathyroid hormone and 1,25-dihydroxyvitamin D3.

4 /kg dose for mice proved less effective than 1,25-dihydroxyvitamin D3.

5 at Cdk6 and Cdk2 activities are regulated by 1,25-dihydroxyvitamin D3.

6 e pretreated with the endogenous VDR agonist 1,25-dihydroxyvitamin D3.

7 tory activity of the receptor independent of 1,25-dihydroxyvitamin D3.

8 ed by Salmonella stimulation, independent of 1,25-dihydroxyvitamin D3.

9 of stimulation with the hormonal VDR ligand, 1,25-dihydroxyvitamin D3.

10 200 genes were identified to be regulated by 1,25-dihydroxyvitamin D3.

11 e that is present in most tissues to produce 1,25-dihydroxyvitamin D3.

12 the kidney to its biologically active form, 1,25-dihydroxyvitamin D3.

13 vated extracellular calcium concentration or 1,25-dihydroxyvitamin D3.

14 ablished GADD45 as a primary target gene for 1,25-dihydroxyvitamin D3.

15 C family in keratinocytes and is induced by 1,25-dihydroxyvitamin D3.

16 n markers involucrin and transglutaminase to 1,25-dihydroxyvitamin D3.

17 ects of IL-1, but not parathyroid hormone or 1, 25-dihydroxyvitamin D3.

18 The ability of 1, 25-dihydroxyvitamin D3 (1,25(OH)2D3) and structural a

19 Transcriptional activation in response to 1, 25-dihydroxyvitamin D3 (1,25-(OH)2D3) was virtually e

20 ial amounts of NO on stimulation with LPS or 1, 25-dihydroxyvitamin D3 (1,25-D3) in the absence of ac

21 time-dependent manner above that induced by 1,25 dihydroxyvitamin D3 (1,25 vitamin D3) in cultures o

22 on in human leukemia HL60 cells treated with 1,25 dihydroxyvitamin D3 (1,25D3) at low to moderately h

23 owing that microRNA-498 (miR-498) induced by 1,25-dihydroxyvitamin D3 (1,25(OH)(2)D(3)) decreases the

24 The biological actions of 1,25-dihydroxyvitamin D3 (1,25(OH)2D3) are mediated by t

25 The hormone 1,25-dihydroxyvitamin D3 (1,25(OH)2D3) elicits the progr

26 1alpha-hydroxylase, the enzyme required for 1,25-dihydroxyvitamin D3 (1,25(OH)2D3) hormone biosynthe

27 ex, plays a fundamental role in induction by 1,25-dihydroxyvitamin D3 (1,25(OH)2D3) of the transcript

28 1,25-Dihydroxyvitamin D3 (1,25(OH)2D3) plays a major rol

29 1,25-Dihydroxyvitamin D3 (1,25(OH)2D3) plays an integral

30 itamin D3 (2MD) is a highly potent analog of 1,25-dihydroxyvitamin D3 (1,25(OH)2D3) whose actions are

31 lase (24(OH)ase), a key metabolic enzyme for 1,25-dihydroxyvitamin D3 (1,25(OH)2D3), is up-regulated

32 way against intracellular M. tuberculosis by 1,25-dihydroxyvitamin D3 (1,25(OH)2D3), the active form

33 1,25-Dihydroxyvitamin D3 (1,25(OH)2D3), the active metab

34 The ability of the active form of vitamin D, 1,25-dihydroxyvitamin D3 (1,25(OH)2D3), to transcription

35 GF)-23, a bone-derived hormone that inhibits 1,25-dihydroxyvitamin D3 (1,25(OH)2D3; calcitriol) forma

36 1,25-Dihydroxyvitamin D3 (1,25-(OH)2D3) down-modulates a

37 tein kinase C (PKC) plays a critical role in 1,25-dihydroxyvitamin D3 (1,25-(OH)2D3) promotion of HL-

38 1,25-Dihydroxyvitamin D3 (1,25-(OH)2D3) suppresses c-myc

39 A quantitative method for measuring 1,25-dihydroxyvitamin D3 (1,25-(OH)2D3) was developed ut

40 1,25-Dihydroxyvitamin D3 (1,25-(OH)2D3), a key regulator

41 Vitamin D3 supports 1,25-dihydroxyvitamin D3 (1,25-[OH]2D3) synthesis in the

42 Treatment with 1,25-dihydroxyvitamin D3 (1,25-D3) normalized TRPC6 expr

43 laboratory has previously demonstrated that 1,25-dihydroxyvitamin D3 (1,25[OH]2D3) rapidly stimulate

44 1,25-dihydroxyvitamin D3 (1,25D), the biologically activ

45 we show that functional AP-1 is required for 1,25-dihydroxyvitamin D3 (1,25D)-induced monocytic diffe

46 e reporter gene transcription in response to 1,25-dihydroxyvitamin D3 (1,25D).

47 n potentiate the transcriptional activity of 1,25-dihydroxyvitamin D3 (1,25D).

48 tic differentiation-inducing steroid hormone 1,25-dihydroxyvitamin D3 (1,25D3) and found that growth

49 We hypothesized that 1,25-dihydroxyvitamin D3 (1,25D3) and its analogues may

50 gical activities and mechanisms of action of 1,25-dihydroxyvitamin D3 (1,25D3) and nine potent 1,25D3

51 In contrast, the active form of vitamin D, 1,25-dihydroxyvitamin D3 (1,25D3), is predominantly immu

52 ere cultured with parathyroid hormone (PTH), 1,25-dihydroxyvitamin D3 (1,25D3), or PTH+1,25D3.

53 lated with all-trans retinoic acid (ATRA) or 1,25-dihydroxyvitamin D3 (1,25D3), the biologically acti

54 sms of acquired drug resistance we developed 1,25-dihydroxyvitamin D3 (1,25D3)-resistant sublines of

55 ll (HSNEC) conversion of 25(OH)D3 (25VD3) to 1,25-dihydroxyvitamin D3 (1,25VD3) and, furthermore, tha

56 Vitamin D3 [1,25-dihydroxyvitamin-D3 (1,25(OH)2D3)] modulates the pr

57 Up-regulation of MKP5 mRNA by 1,25-dihydroxyvitamin-D3 (1,25D) was dependent on the vi

58 that AXII gene expression is upregulated by 1,25-dihydroxyvitamin D3 [1, 25-(OH)2D3] and that additi

59 ts in elevated serum phosphate, calcium, and 1,25-dihydroxyvitamin D3 [1,25(OH)(2)D] levels; vascular

60 We investigated the capacity of 1,25-dihydroxyvitamin D3 [1,25(OH)2D3] and all-trans-ret

61 ne is regulated by extracellular calcium and 1,25-dihydroxyvitamin D3 [1,25(OH)2D3] and GHS rats have

62 ifferentiate normally under the influence of 1,25-dihydroxyvitamin D3 [1,25(OH)2D3] despite the prese

63 single known regulatory mediator of hormonal 1,25-dihydroxyvitamin D3 [1,25(OH)2D3] in higher vertebr

64 nce between bioactivation and degradation of 1,25-dihydroxyvitamin D3 [1,25(OH)2D3] is critical for e

65 1,25-Dihydroxyvitamin D3 [1,25(OH)2D3] is the biological

66 The 1,25-dihydroxyvitamin D3 [1,25(OH)2D3] is the physiologi

67 estinal Ca hyperabsorption with normal serum 1,25-dihydroxyvitamin D3 [1,25(OH)2D3] levels, elevation

68 le diet (WD) and supplemental calcium and/or 1,25-dihydroxyvitamin D3 [1,25(OH)2D3] on the colorectal

69 e potential functional significance of human 1,25-dihydroxyvitamin D3 [1,25(OH)2D3] receptor (hVDR) p

70 higher levels of the osteoregulatory steroid 1,25-dihydroxyvitamin D3 [1,25(OH)2D3] than whites.

71 ll stimuli and transcriptional repression by 1,25-dihydroxyvitamin D3 [1,25(OH)2D3] through the vitam

72 In experimental models and clinical trials, 1,25-dihydroxyvitamin D3 [1,25(OH)2D3] was shown to exer

73 itamin D deficiency, and its bioactive form, 1,25-dihydroxyvitamin D3 [1,25(OH)2D3], has been shown t

74 The active form of vitamin D, 1,25-dihydroxyvitamin D3 [1,25(OH)2D3], has been shown t

75 The biologically active form of vitamin D, 1,25-dihydroxyvitamin D3 [1,25(OH)2D3], is able to promo

76 High doses of the active form of vitamin D3, 1,25-dihydroxyvitamin D3 [1,25(OH)2D3], prevent diabetes

77 The receptors for 9-cis retinoic acid and 1,25-dihydroxyvitamin D3 [1,25(OH)2D3], RXR and VDR, res

78 1,25-Dihydroxyvitamin D3 [1,25(OH)2D3], the active metab

79 1,25-Dihydroxyvitamin D3 [1,25(OH)2D3], the hormonal lig

80 (CYP24A1) with 25(OH)D3, 3-epi-25(OH)D3, and 1,25-dihydroxyvitamin D3 [1,25(OH)2D3]; and 1alpha-hydro

81 ndex over the naturally occurring VDR ligand 1,25-dihydroxyvitamin D3 [1,25-(OH)2D3] in an in vivo pr

82 ompletely prevented by the administration of 1,25-dihydroxyvitamin D3 [1,25-(OH)2D3].

83 nal vitamin D receptor (VDR) is required for 1,25-dihydroxyvitamin D3-[1,25(OH)2D3]-induced renal rea

84 The active form of vitamin D3 (1,25-dihydroxyvitamin D3; 1,25(OH)2D3) inhibits prolifer

85 2-Methylene-19-nor-(20S)-1,25-dihydroxyvitamin D3 (2MD) is a highly potent analog

86 cidence of ACR compared to no treatment with 1,25-dihydroxyvitamin D3 (5.1% vs. 13.0%, P=0.099).

87 nor-1,25-dihydroxyvitamin D2 (200 ng/day) or 1,25-dihydroxyvitamin D3 (50 ng/mouse/day) orally throug

88 retinoid exposure was potently attenuated by 1,25-dihydroxyvitamin D3, a metabolic vitamin derivative

89 The hormonal form of vitamin D, 1,25-dihydroxyvitamin D3, acting through its cognate nuc

90 To understand the molecular mechanism of 1,25-dihydroxyvitamin D3 action, we profiled the hormone

91 Retinoic acid and 1, 25-dihydroxyvitamin D3 activate both a genomic fragme

92 e transient gene expression system augmented 1, 25-dihydroxyvitamin D3-activated transcription, but i

93 verts 25-hydroxyvitamin D3 (storage form) to 1,25-dihydroxyvitamin D3 (active form).

94 Furthermore, CsA causes bone loss, whereas 1,25-dihydroxyvitamin D3 actually increases bone mass.

95 To support this belief, we have found that 1,25-dihydroxyvitamin D3 administration to mice increase

96 m and inositol triphosphate levels following 1,25-dihydroxyvitamin D3 administration were markedly re

97 e C-gamma1 construct were measured following 1,25-dihydroxyvitamin D3 administration.

98 intracellular calcium mobilization following 1,25-dihydroxyvitamin D3 administration.

99 extremely high serum levels of phosphate and 1,25-dihydroxyvitamin D3, along with abnormal bone miner

100 The use of 1,25-dihydroxyvitamin D3 and its analogs to increase tra

101 r patients to benefit from therapy with both 1,25-dihydroxyvitamin D3 and ligands for death receptors

102 Because of the role of 1,25-dihydroxyvitamin D3 and retinoic acid working throu

103 aT1 in the intestine is highly responsive to 1,25-dihydroxyvitamin D3 and shows both fast and slow ca

104 Our findings reveal a novel activity of 1,25-dihydroxyvitamin D3 and the VDR in regulation of pr

105 data in the literature support the idea that 1,25-dihydroxyvitamin D3 and the vitamin D receptor (VDR

106 In this study, we show that 1,25-dihydroxyvitamin D3 and three of its analogs induce

107 The role for 1,25-dihydroxyvitamin D3 and/or calcium in hair follicle

108 orbol-13-acetate [TPA], gamma interferon, or 1, 25-dihydroxyvitamin D3) and then challenged with HGE.

109 aride (LPS), estradiol, progesterone, and/or 1,25-dihydroxyvitamin D3; and transcriptional activity o

110 tudying the regulation of gene expression by 1,25-dihydroxyvitamin D3, as well as for examining facto

111 ne resorption in organ culture stimulated by 1,25-dihydroxyvitamin D3 at concentrations as low as 75

112 We find that 1,25 dihydroxyvitamin D3 binding favors both VDR-RXR het

113 Previously we demonstrated that 1,25-dihydroxyvitamin D3 blocks the progression of relap

114 We now propose that 1,25-dihydroxyvitamin D3 blocks these autoimmune symptom

115 Here, we found that 1,25-dihydroxyvitamin D3-bound [1,25(OH)2D3-bound] vitam

116 ic acid attenuates the stimulating effect of 1,25-dihydroxyvitamin D3 by decreasing the rate of VDR-R

117 ulture-derived HCV were exposed to bioactive 1,25-dihydroxyvitamin D3 (calcitriol) with or without IF

118 monstrate that the active form of vitamin D, 1,25-dihydroxyvitamin D3 (calcitriol), has a profound in

119 These results suggest that 1,25-dihydroxyvitamin D3 can be used as an effective age

120 Results show that 1,25-dihydroxyvitamin D3 can either prevent or markedly

121 The present study showed that 1,25-dihydroxyvitamin D3 causes cell cycle arrest at the

122 (PTH) significantly (p=0.0172), while serum 1,25-dihydroxyvitamin D3 concentration was not changed b

123 were immunized with pWW65 alone, pWW65 plus 1,25-dihydroxyvitamin-D3 (D3), or pRSVnt.

124 on of the death receptors, pretreatment with 1,25-dihydroxyvitamin D3 decreased apoptosis induced by

125 that endogenous NCoA62/SKIP associated in a 1,25-dihydroxyvitamin D3-dependent manner with VDR targe

126 at associate with the receptor in a strictly 1,25-dihydroxyvitamin D3-dependent manner.

127 ver, EVs from osteoclast precursors promoted 1,25-dihydroxyvitamin D3-dependent osteoclast formation

128 eract with the AF-2 domain of VDR to augment 1,25-dihydroxyvitamin D3-dependent transcription.

129 1,25-Dihydroxyvitamin D3 (DHVD3) coadministered with mon

130 1,25-Dihydroxyvitamin D3 does not suppress basal promote

131 1,25-Dihydroxyvitamin D3 enhanced LTBP1 cleavage, result

132 We also observed that 1,25-dihydroxyvitamin D3 enhanced the inhibition of T ce

133 1,25-Dihydroxyvitamin D3 exerts its effects by binding t

134 DNA or GADD45-null mouse embryo fibroblasts, 1,25-dihydroxyvitamin D3 failed to induce G2/M arrest.

135 The hormone 1,25-dihydroxyvitamin D3 has been most extensively studi

136 In the 1,25-dihydroxyvitamin D3 HL60 cell system, G1 arrest has

137 how that p21 is transcriptionally induced by 1,25-dihydroxyvitamin D3 in a VDR-dependent, but not p53

138 diator for the tumor-suppressing activity of 1,25-dihydroxyvitamin D3 in human ovarian cancer cells.

139 The efficacy of 1,25-dihydroxyvitamin D3 in prolonging graft survival in

140 ependent induction of luciferase activity by 1,25-dihydroxyvitamin D3 in reporter assays.

141 by an absent response of her fibroblasts to 1,25-dihydroxyvitamin D3 in vitro.

142 opriate splicing of transcripts derived from 1,25-dihydroxyvitamin D3-induced expression of a growth

143 important in the signaling pathway mediating 1,25-dihydroxyvitamin-D3-induced keratinocyte differenti

144 in the signal transduction pathway mediating 1,25-dihydroxyvitamin-D3-induced keratinocyte differenti

145 -II and RA 4-hydroxylase, but did not affect 1,25-dihydroxyvitamin D3 induction of the vitamin D rece

146 n A (all-trans retinoic acid) and vitamin D (1,25-dihydroxyvitamin D3) inhibited P. acnes-induced Th1

147 Thus, like cyclosporin A, 1,25-dihydroxyvitamin D3 inhibits TCR-driven activation,

148 The active metabolite of vitamin D, 1,25 dihydroxyvitamin D3, is an important immunoregulato

149 nd normalized serum 25-hydroxyvitamin D3 and 1,25-dihydroxyvitamin D3 levels, as well as mineral and

150 nti-human CD14 Abs blocked the activation of 1,25-dihydroxyvitamin D3-matured human myelomonocytic TH

151 These studies suggest that 1,25-dihydroxyvitamin D3 may be effective in prolonging

152 of these two anti-inflammatory cytokines by 1,25-dihydroxyvitamin D3 may be responsible for the abil

153 Locally produced 1,25-dihydroxyvitamin D3 may have pleiotropic effects ou

154 y important roles in mediating the action of 1,25-dihydroxyvitamin D3 on involucrin expression, but t

155 pproach to overcome the protective effect of 1,25-dihydroxyvitamin D3 on the apoptosis of ovarian can

156 ed transcriptional repression in response to 1,25-dihydroxyvitamin D3 or 17beta-estradiol.

157 The provision of exogenous 1,25-dihydroxyvitamin D3 or an analog, 19-nor-1,25-dihyd

158 he induction of osteoclastogenesis by either 1,25-dihydroxyvitamin D3 or dexamethasone.

159 ced osteoclast-like MNC formation induced by 1,25-dihydroxyvitamin D3 or PTH-related protein in mouse

160 9-cis or all-trans retinoic acid, 1,25 dihydroxyvitamin D3, or the PPARgamma ligands prost

161 Recently, we have shown that 1,25-dihydroxyvitamin D3 prolongs graft survival in mice

162 Our results suggest that 1,25-dihydroxyvitamin D3 prolongs graft survival without

163 At followup, levels of 1,25-dihydroxyvitamin D3, PTH, OC, and urine phosphorus

164 Many nuclear receptors, including the human 1,25-dihydroxyvitamin D3 receptor (VDR), bind cooperativ

165 clear hormone receptors, including the human 1,25-dihydroxyvitamin D3 receptor (VDR), bind cooperativ

166 veloping fetal rat which immunostain for the 1,25-dihydroxyvitamin D3 receptor (VDR).

167 nt studies suggest that growth inhibition by 1,25-dihydroxyvitamin D3 represents an innovative approa

168 esponse element provides specificity for the 1,25-dihydroxyvitamin D3 response lacking at the AP-1 si

169 nhibitor p27 in U937 cells in the absence of 1,25-dihydroxyvitamin D3 results in the cell-surface exp

170 on of Fas relieved the suppressive effect of 1,25-dihydroxyvitamin D3, showing that molecular manipul

171 rived EVs to inhibit osteoclast formation in 1,25-dihydroxyvitamin D3-stimulated marrow cultures.

172 AP-1 site reduced basal activity and blocked 1,25-dihydroxyvitamin D3 stimulation of the involucrin p

173 udy both elements proved to be important for 1,25-dihydroxyvitamin D3 stimulation of the involucrin p

174 n of involucrin gene expression, but blocked 1,25-dihydroxyvitamin D3 stimulation.

175 1,25-Dihydroxyvitamin D3 supplementation initiated withi

176 the first year of kidney transplantation and 1,25-dihydroxyvitamin D3 supplementation may help reduce

177 ancer cells express vitamin D3 receptors and 1,25-dihydroxyvitamin D3 suppressed growth of these cell

178 1,25-Dihydroxyvitamin D3 suppresses the growth of multip

179 1,25-Dihydroxyvitamin D3, the hormonal form of vitamin D

180 These results support the hypothesis that 1, 25-dihydroxyvitamin D3, through interactions with the

181 sity, femurs were collected from nontreated, 1,25-dihydroxyvitamin D3-treated (50 ng/mouse/day), or C

182 were higher in the central nervous system of 1,25-dihydroxyvitamin D3-treated mice compared with cont

183 of cells recoverable from the lymph nodes of 1,25-dihydroxyvitamin D3-treated mice was only 50% that

184 cell line with probes generated from either 1,25-dihydroxyvitamin D3-treated or untreated cells.

185 We compared the ability of 1,25-dihydroxyvitamin D3-treated, nontreated, or cyclosp

186 Overall, 1,25-dihydroxyvitamin D3 treatment causes a net loss in

187 Here we show that 1,25-dihydroxyvitamin D3 treatment does not increase the

188 Because persistent 1,25-dihydroxyvitamin D3 treatment has been shown to ind

189 of ovalbumin (OVA) model allergen, CpG, and 1,25-dihydroxyvitamin D3 (VD3).

190 the multifunctional regulator YY1 represses 1,25-dihydroxyvitamin D3 (vitamin D)-induced transactiva

191 rvival of the transplants brought about with 1,25-dihydroxyvitamin D3 was not accompanied by hypercal

192 n D3 and convert it to the most active form, 1,25-dihydroxyvitamin D3, which regulates keratinocyte p

193 To test the hypothesis that 1,25-dihydroxyvitamin D3 would prolong allograft surviva